• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by CASI Pharmaceuticals Inc. (Amendment)

    2/21/23 7:33:47 AM ET
    $CASI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CASI alert in real time by email
    SC 13D/A 1 dp189149_13da-5.htm FORM SC 13D/A

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, DC 20549

     

    SCHEDULE 13D

    (Amendment No.5)

    Under the Securities Exchange Act of 1934

     

    CASI PHARMACEUTICALS, INC.

    (Name of Issuer)

     

    Common Stock, $0.01 par value

    (Title of Class of Securities)

    14757U 109

    (CUSIP Number)

     

    Chi Sing Ho

    c/o IDG Capital Management (HK) Company Limited

    Unit 5505, The Center

    99 Queen’s Road, Central

    Hong Kong

    (Name, Address and Telephone Number of Person

    Authorized to Receive Notices and Communications)

     

    June 1, 2022

    (Date of Event Which Requires Filing of This Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), Rule 13d-1(f) or Rule 13d-1(g), check the following box. ☐

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

    1. Name of Reporting Person
      IDG-Accel China Growth Fund III L.P.

     

    2. Check the Appropriate Box if a Member of a Group
    (a) ☐
    (b) ☐
         

    3. SEC Use Only
    4. Source of Funds (See Instructions)
      AF

     

    5. Check if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e) ☐

     

    6.

    Citizenship or Place of Organization

    Cayman Islands

     

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With

    7. Sole Voting Power

    912,636 (1)

    8. Shared Voting Power

    64,698 (2)

    9. Sole Dispositive Power

    912,636 (1)

    10. Shared Dispositive Power

    64,698 (2)

     

    11. Aggregate Amount Beneficially Owned by Each Reporting Person
      977,334

     

    12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) ☐

     

    13. Percent of Class Represented by Amount in Row 11
      7.2%(3)

     

    14.

    Type of Reporting Person (See Instructions)

    PN

     

    (1) These securities include (i) 797,353 shares of common stock issued by the Issuer to the Reporting Person and (ii) 115,283 shares of common stock issuable upon exercise at $36.9 per share of certain warrants issued by the Issuer to the Reporting Person.

     

    (2) These securities include (i) 56,526 shares of common stock held by IDG-Accel China III Investors L.P. (“IDG-Accel Investors”) and (ii) 8,172 shares of common stock issuable upon exercise at $36.9 per share of certain warrants issued by the Issuer to IDG-Accel Investors. The Reporting Person has the same ultimate general partner, IDG-Accel China Growth Fund GP III Associates Ltd., as IDG-Accel Investors. By virtue of this affiliation, the Reporting Person may be deemed to be under common control with IDG-Accel Investors and thus share voting and dispositive power with respect to these shares.

     

    (3) Based on 13,457,625 shares of common stock outstanding as of December 31, 2022, as reported in the Proxy Statement on Form DEF 14A of the Issuer filed with the Securities and Exchange Commission on February 14, 2023.

     

     

     

    1. Name of Reporting Person
      IDG-Accel China III Investors L.P.

     

    2. Check the Appropriate Box if a Member of a Group
    (a) ☐
    (b) ☐
         

    3. SEC Use Only

     

    4. Source of Funds (See Instructions)
      AF

     

    5. Check if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e) ☐

     

    6.

    Citizenship or Place of Organization

    Cayman Islands

     

    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person
    With

    7. Sole Voting Power
    64,698
    (1)

    8. Shared Voting Power

    912,636 (2)

    9. Sole Dispositive Power

    64,698 (1)

    10. Shared Dispositive Power

    912,636 (2)

     

    11. Aggregate Amount Beneficially Owned by Each Reporting Person
      977,334

     

    12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) ☐

     

    13. Percent of Class Represented by Amount in Row 11
      7.2%(3)

     

    14.

    Type of Reporting Person (See Instructions)

    PN

     

    (1) These securities include (i) 56,526 shares of common stock issued by the Issuer to the Reporting Person and (ii) 8,172 shares of common stock issuable upon exercise at $36.9 per share of certain warrants issued by the Issuer to the Reporting Person.

     

    (2) These securities include (i) 797,353 shares of common stock held by IDG-Accel China Growth Fund III L.P. (“IDG-Accel Growth”) and (ii) 115,283 shares of common stock issuable upon exercise at $36.9 per share of certain warrants issued by the Issuer to IDG-Accel Growth. The Reporting Person has the same ultimate general partner, IDG-Accel China Growth Fund GP III Associates Ltd., as IDG-Accel Growth. By virtue of this affiliation, the Reporting Person may be deemed to be under common control with IDG-Accel Growth and thus share voting and dispositive power with respect to these shares.

     

    (3) Based on 13,457,625 shares of common stock outstanding as of December 31, 2022, as reported in the Proxy Statement on Form DEF 14A of the Issuer filed with the Securities and Exchange Commission on February 14, 2023.

     

     

     

    1. Name of Reporting Person
      IDG-Accel China Growth Fund III Associates L.P.

     

    2. Check the Appropriate Box if a Member of a Group
    (a) ☐
    (b) ☐
         

    3. SEC Use Only

     

    4. Source of Funds (See Instructions)
      AF

     

    5. Check if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e) ☐

     

    6.

    Citizenship or Place of Organization

    Cayman Islands

     

    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person
    With

    7. Sole Voting Power

    912,636 (1)

    8. Shared Voting Power

    64,698 (2)

    9. Sole Dispositive Power

    912,636 (1)

    10. Shared Dispositive Power

    64,698 (2)

     

    11. Aggregate Amount Beneficially Owned by Each Reporting Person
      977,334

     

    12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) ☐

     

    13. Percent of Class Represented by Amount in Row 11
      7.2%(3)

     

    14.

    Type of Reporting Person (See Instructions)

    PN

     

    (1) These securities include (i) 797,353 shares of common stock issued by the Issuer to IDG-Accel Growth; and (ii) 115,283 shares of common stock issuable upon exercise at $36.9 per share of certain warrants by the Issuer to IDG-Accel Growth. The Reporting Person is the sole general partner of IDG-Accel Growth. By virtue of this affiliation, the Reporting Person may be deemed to have sole voting and dispositive power with respect to all these securities.

     

    (2) These securities include (i) 56,526 shares of common stock held by IDG-Accel Investors and (ii) 8,172 shares of common stock issuable upon exercise at $36.9 per share of certain warrants issued by the Issuer to IDG-Accel Investors. The Reporting Person has the same general partner, IDG-Accel China Growth Fund GP III Associates Ltd. as IDG-Accel Investors. By virtue of this affiliation, the Reporting Person may be deemed to be under common control with IDG-Accel Investors and thus share voting and dispositive power with respect to these shares.

     

    (3) Based on 13,457,625 shares of common stock outstanding as of December 31, 2022, as reported in the Proxy Statement on Form DEF 14A of the Issuer filed with the Securities and Exchange Commission on February 14, 2023.

     

     

     

    1. Name of Reporting Person
      IDG-Accel China Growth Fund GP III Associates Ltd.

     

    2. Check the Appropriate Box if a Member of a Group
    (a) ☐
    (b) ☐

     

    3. SEC Use Only

     

    4. Source of Funds (See Instructions)
      AF

     

    5. Check if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e) ☐

     

    6.

    Citizenship or Place of Organization

    Cayman Islands

     

    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person
    With

    7. Sole Voting Power

    977,334 (1)

    8. Shared Voting Power

    0

    9. Sole Dispositive Power

    977,334 (1)

    10. Shared Dispositive Power

    0

     

    11. Aggregate Amount Beneficially Owned by Each Reporting Person
      977,334

     

    12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) ☐

     

    13. Percent of Class Represented by Amount in Row 11
      7.2%(2)

     

    14.

    Type of Reporting Person (See Instructions)

    CO

     

    (1) These securities include (i) 797,353 shares of common stock issued by the Issuer to IDG-Accel Growth ; (ii) 115,283 shares of common stock issuable upon exercise at $36.9 per share of certain warrants issued by the Issuer to IDG-Accel Growth; (iii) 56,526 shares of common stock issued by the Issuer to IDG-Accel Investors; and (iv) 8,172 shares of common stock issuable upon exercise at $36.9 per share of certain warrants issued by the Issuer to IDG-Accel Investors. The Reporting Person is the ultimate general partner of both IDG-Accel Growth and IDG-Accel Investors. By virtue of this affiliation, the Reporting Person may be deemed to have voting and dispositive power with respect to all these shares.

     

    (2) Based on 13,457,625 shares of common stock outstanding as of December 31, 2022, as reported in the Proxy Statement on Form DEF 14A of the Issuer filed with the Securities and Exchange Commission on February 14, 2023.

     

     

     

    1. Name of Reporting Person
      Chi Sing Ho

     

    2. Check the Appropriate Box if a Member of a Group
    (a) ☐
    (b) ☐

     

    3. SEC Use Only

     

    4. Source of Funds (See Instructions)
      AF

     

    5. Check if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e) ☐

     

    6.

    Citizenship or Place of Organization

    Canada

     

    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person
    With

    7. Sole Voting Power

    0

    8. Shared Voting Power

    977,334 (1)

    9. Sole Dispositive Power

    0

    10. Shared Dispositive Power

    977,334 (1)

     

    11. Aggregate Amount Beneficially Owned by Each Reporting Person
      977,334

     

    12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) ☐

     

    13. Percent of Class Represented by Amount in Row 11
      7.2%(2)

     

    14.

    Type of Reporting Person (See Instructions)

    IN

     

    (1) These securities include (i) 797,353 shares of common stock issued by the Issuer to IDG-Accel Growth; (ii) 115,283 shares of common stock issuable upon exercise at $36.9 per share of certain warrants issued by the Issuer to IDG-Accel Growth; and (iii) 56,526 shares of common stock issued by the Issuer to IDG-Accel Investors; and (iv) 8,172 shares of common stock issuable upon exercise at $36.9 per share of certain warrants issued by the Issuer to IDG-Accel Investors.. The Reporting Person and Quan Zhou are directors and shareholders of IDG-Accel China Growth Fund GP III Associates Ltd., the ultimate general partner of IDG-Accel Growth and IDG-Accel Investors, thus may be deemed to share voting and dispositive power with respect to all these shares.

     

    (2) Based on 13,457,625 shares of common stock outstanding as of December 31, 2022, as reported in the Proxy Statement on Form DEF 14A of the Issuer filed with the Securities and Exchange Commission on February 14, 2023.

     

     

     

    1. Name of Reporting Person
      Quan Zhou

     

    2. Check the Appropriate Box if a Member of a Group
    (a) ☐
    (b) ☐
         
    3. SEC Use Only

     

    4. Source of Funds (See Instructions)
      AF

     

    5. Check if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e) ☐

     

    6.

    Citizenship or Place of Organization

    United States

     

    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person
    With

    7. Sole Voting Power

    76,304(1)

    8. Shared Voting Power

    977,334 (2)

    9. Sole Dispositive Power

    76,304(1)

    10. Shared Dispositive Power

    977,334 (2)

     

    11. Aggregate Amount Beneficially Owned by Each Reporting Person
      1,053,638

     

    12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) ☐

     

    13. Percent of Class Represented by Amount in Row 11
      7.7%(3)

     

    14.

    Type of Reporting Person (See Instructions)

    IN

     

    (1) These securities include 76,304 shares of common stock issuable upon exercise of certain options issued by the Issuer to Quan Zhou.

     

    (2) These securities include (i) 797,353 shares of common stock issued by the Issuer to IDG-Accel Growth; (ii) 115,283 shares of common stock issuable upon exercise at $36.9 per share of certain warrants issued by the Issuer to IDG-Accel Growth; (iii) 56,526 shares of common stock issued by the Issuer to IDG-Accel Investors; and (iv) 8,172 shares of common stock issuable upon exercise at $36.9 per share of certain warrants issued by the Issuer to IDG-Accel Investors. The Reporting Person and Chi Sing Ho are directors and shareholders of IDG-Accel China Growth Fund GP III Associates Ltd., the ultimate general partner of IDG-Accel Growth and IDG-Accel Investors, thus may be deemed to share voting and dispositive power with respect to all these shares.

     

    (3) Based on 13,457,625 shares of common stock outstanding as of December 31, 2022, as reported in the Proxy Statement on Form DEF 14A of the Issuer filed with the Securities and Exchange Commission on February 14, 2023.

     

     

     

    This Amendment No. 5 amends the Statement on Schedule 13D dated January 30, 2012 as amended by Amendment No. 1 dated February 2, 2012, Amendment No. 2 dated June 11, 2012, Amendment No. 3 dated March 6, 2013 and Amendment No. 4 dated March 20, 2018 (as so amended, the “Original 13D”) and is being filed to reflect changes in the number and percentage of shares of Common Stock beneficially owned by the Reporting Persons due to (a) a ten-to-one reverse stock split of the Issuer’s Common Stock that was effectuated by the Issuer on June 1, 2022 and (b) increase in the amount of total issued and outstanding Common Stock over time. Except as amended and supplemented herein, the information set forth in the Original Schedule 13D remains unchanged. Capitalized terms used herein have meanings as assigned thereto in the Original Schedule 13D, unless defined herein.

     

    Item 5. Interest in Securities of the Issuer.

     

    Items 5(a) - (b) of the Original Schedule 13D are hereby amended and restated in its entirety as follows:

     

    (a) Each of the Reporting Persons’ current ownership in the Issuer and the Common Stock is set forth on the cover pages to this Statement on Schedule 13D and is incorporated by reference herein. The ownership percentage appearing on such pages has been calculated based on a total of 13,457,625 shares of Common Stock outstanding as of December 31, 2022, as reported in the Proxy Statement on Form DEF 14A of the Issuer filed with the SEC on February 14, 2023. The Reporting Persons disclaim membership in any “group” with any person other than the Reporting Persons. The filing of this Statement on Schedule 13D by the Reporting Persons shall not be considered an admission that such Reporting Persons, for the purpose of Section 13(d) of the Exchange Act, are the beneficial owners of any of the shares of Common Stock covered in this Statement on Schedule 13D, and the Reporting Persons expressly disclaim such beneficial ownership.

     

    (b) The following table sets forth the beneficial ownership of shares of Common Stock for each of the Reporting Persons.

     

    Reporting Person Number of Shares of Common Stock Beneficially Owned Percentage of Common Stock Sole Power to Vote/Direct Vote Shared Power to Vote/Direct Vote Sole Power to Dispose/Direct Disposition Shared Power to Dispose/Direct Disposition
    IDG-Accel Growth 977,334 7.2% 912,636 64,698 912,636 64,698
    IDG-Accel Investors 977,334 7.2% 64,698 912,636 64,698 912,636
    IDG-Accel Associates 977,334 7.2% 912,636 64,698 912,636 64,698
    IDG-Accel GP 977,334 7.2% 977,334 0 977,334 0
    Chi Sing Ho 977,334 7.2% 0 977,334 0 977,334
    Quan Zhou 1,053,638 7.7% 76,304 977,334 76,304 977,334

     

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, the undersigned certify that the information set forth in this Statement is true, complete and correct.

     

    IDG-ACCEL CHINA GROWTH FUND III L.P.
    By: IDG- Accel China Growth Fund III Associates L.P.
    its General Partner
    By: IDG-Accel China Growth Fund GP III Associates Ltd.
    its General Partner
    By: /s/ Chi Sing Ho
    Name: Chi Sing Ho
    Title: Authorized Signatory
    Dated: February 21, 2023



    IDG-ACCEL CHINA III INVESTORS L.P.

    By: IDG-Accel China Growth Fund GP III Associates Ltd.
    its General Partner
    By: /s/ Chi Sing Ho
    Name: Chi Sing Ho
    Title: Authorized Signatory
    Dated: February 21, 2023



    IDG-ACCEL CHINA GROWTH FUND III ASSOCIATES L.P.

    By: IDG-Accel China Growth Fund GP III Associates Ltd.
    its General Partner
    By: /s/ Chi Sing Ho
    Name: Chi Sing Ho
    Title: Authorized Signatory
    Dated: February 21, 2023



    IDG-ACCEL CHINA GROWTH FUND GP III ASSOCIATES LTD.

    By: /s/ Chi Sing Ho
    Name: Chi Sing Ho
    Title: Authorized Signatory
    Dated: February 21, 2023


    Chi Sing Ho
    By: /s/ Chi Sing Ho
    Name: Chi Sing Ho
    Dated: February 21, 2023



    Quan Zhou

    By: /s/ Quan Zhou
    Name: Quan Zhou
    Dated: February 21, 2023

     

     

     

    Get the next $CASI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CASI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CASI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • CASI Announces First Patient Dosed in Phase 1/2 Clinical Trial of CID-103 in Immune Thrombocytopenia

      BEIJING, CHINA / ACCESSWIRE / January 6, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a biopharmaceutical company specializing in the development and commercialization of innovative therapeutic and pharmaceutical products announced that the first patient has been dosed in the Phase 1/2 trial to evaluate the safety and tolerability of CID-103 in adult patients with chronic Immune Thrombocytopenia (ITP) in China."Dosing the first patient in our phase 1/2 study marks a significant milestone for both CID-103 program and chronic ITP patients who have limited treatment options," said Dr. Wei-Wu He, Chairman and CEO of CASI, "The rapid execution underscores our commitment to accelerating clinic

      1/6/25 8:00:00 AM ET
      $CASI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CASI Pharmaceuticals Announces Third Quarter 2024 Business and Financial Results

      BEIJING, CHINA / ACCESSWIRE / November 15, 2024 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI) ("CASI" or the "Company"), a Cayman incorporated biopharmaceutical company specializing in the development and commercialization of innovative therapeutics and pharmaceutical products, today reported business updates and financial results for the three months ended September 30, 2024.Dr. Wei-Wu He, Chairman and CEO of CASI, said "The third quarter of 2024 marks a period of substantial progress for CASI as we continue to refine our company's strategic focus on the development for organ transplant rejection and autoimmune diseases. We just announced the Center for Drug Evaluation (CDE) of China's Nationa

      11/15/24 8:00:00 AM ET
      $CASI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CASI Pharmaceuticals Receives CTA Approval From China's NMPA for CID-103 in Immune Thrombocytopenia

      BEIJING, CHINA / ACCESSWIRE / October 24, 2024 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a biopharmaceutical company specializing in the development and commercialization of innovative therapeutic and pharmaceutical products announced that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has approved the Company's Clinical Trial Application (CTA) to proceed with a phase 1/2 study of CID-103 in adults patients with chronic Immune Thrombocytopenia (ITP) in China. This China study is part of the global study that was approved by the US FDA in May 2024.CID-103 is a fully human IgG1 anti-CD38 monoclonal antibody recognizing a unique epitope that ha

      10/24/24 8:00:00 AM ET
      $CASI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CASI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Zukiwski Alexander A

      4 - CASI Pharmaceuticals, Inc. (0000895051) (Issuer)

      9/9/22 4:01:37 PM ET
      $CASI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Huang James bought $229,662 worth of shares (55,573 units at $4.13)

      4 - CASI Pharmaceuticals, Inc. (0000895051) (Issuer)

      9/8/22 6:51:39 PM ET
      $CASI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Huang James bought $139,036 worth of shares (37,196 units at $3.74)

      4 - CASI Pharmaceuticals, Inc. (0000895051) (Issuer)

      9/2/22 7:35:18 PM ET
      $CASI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CASI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BTIG Research initiated coverage on CASI Pharma with a new price target

      BTIG Research initiated coverage of CASI Pharma with a rating of Buy and set a new price target of $4.00

      5/18/21 6:41:48 AM ET
      $CASI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on CASI Pharmaceuticals with a new price target

      HC Wainwright & Co. reiterated coverage of CASI Pharmaceuticals with a rating of Buy and set a new price target of $4.00 from $3.50 previously

      5/14/21 6:40:01 AM ET
      $CASI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mizuho initiated coverage on CASI Pharmaceuticals with a new price target

      Mizuho initiated coverage of CASI Pharmaceuticals with a rating of Buy and set a new price target of $3.80

      4/26/21 7:19:24 AM ET
      $CASI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CASI
    Leadership Updates

    Live Leadership Updates

    See more
    • CASI Pharmaceuticals announces appointment of Daniel Lang, MD as CFO and SVP

      BEIJING, July 8, 2024 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products today announces appointment of Daniel Lang, MD as Chief Financial Officer and Senior Vice President, effective July 8th, 2024. Dr. Lang has more than 30 years of experience as a physician scientist, investor, and biotech executive. He is a cardiologist by training from UCSF, followed by 20 years of investment experience as a portfolio manager at Farallon Capi

      7/8/24 7:30:00 AM ET
      $CASI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CASI
    Financials

    Live finance-specific insights

    See more
    • Ligand Reports Second Quarter 2024 Financial Results

      Conference call at 4:30 p.m. Eastern Time today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and six months ended June 30, 2024, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 4:30 p.m. Eastern Time to discuss this announcement and answer questions. "We had a strong quarter and are on track to meet the long-term growth objectives we outlined in December," said Todd Davis, CEO of Ligand. "We added four new commercial-stage programs in the first half of this year, including QARZIBA®, an orphan oncology product we acquired following the APEIRON Biologics transacti

      8/6/24 4:01:00 PM ET
      $AGEN
      $AMGN
      $CASI
      $LGND
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Ligand Reports First Quarter 2024 Financial Results

      Conference Call Begins at 4:30 p.m. Eastern Time Today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three months ended March 31, 2024, and provided an operating forecast and business updates. Ligand management will host a conference call today beginning at 4:30 p.m. Eastern Time to discuss this announcement and answer questions. "We are pleased to report another quarter of strong financial results driven by the performance of our commercial royalty portfolio. Simultaneously, we continue to build our portfolio of development stage royalty assets to deliver future growth," said Todd Davis, CEO of Ligand. "We continue to originate a robust pipe

      5/7/24 4:00:00 PM ET
      $AMGN
      $CASI
      $JAZZ
      $LGND
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • CASI Pharmaceuticals Acquires Global Intellectual Property Rights to Cleave Therapeutics' VCP/P97 Inhibitor CB-5339

      BEIJING, July 20, 2023 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced the execution of the Assignment Agreement (the "Agreement") with Cleave Therapeutics, Inc. ("Cleave"), pursuant to which CASI obtained all rights and global intellectual property rights related to CB-5339, a novel VCP/p97 inhibitor, as well as all remaining CB-5339 drug substance and drug product. Additionally, CASI will assume responsibility of the United States ("US") CB-5339 Investigational New Drug ("IND") application.

      7/20/23 8:00:00 AM ET
      $CASI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CASI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by CASI Pharmaceuticals Inc.

      SC 13G/A - CASI Pharmaceuticals, Inc. (0001962738) (Subject)

      10/29/24 4:05:28 PM ET
      $CASI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by CASI Pharmaceuticals Inc.

      SC 13D/A - CASI Pharmaceuticals, Inc. (0001962738) (Subject)

      8/12/24 8:27:51 AM ET
      $CASI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by CASI Pharmaceuticals Inc.

      SC 13G - CASI Pharmaceuticals, Inc. (0001962738) (Subject)

      7/25/24 8:48:03 PM ET
      $CASI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CASI
    SEC Filings

    See more
    • SEC Form 6-K filed by CASI Pharmaceuticals Inc.

      6-K - CASI Pharmaceuticals, Inc. (0001962738) (Filer)

      5/20/25 8:31:31 AM ET
      $CASI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form 6-K/A filed by CASI Pharmaceuticals Inc.

      6-K/A - CASI Pharmaceuticals, Inc. (0001962738) (Filer)

      5/20/25 8:00:22 AM ET
      $CASI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by CASI Pharmaceuticals Inc.

      6-K - CASI Pharmaceuticals, Inc. (0001962738) (Filer)

      5/16/25 8:30:18 AM ET
      $CASI
      Biotechnology: Pharmaceutical Preparations
      Health Care